Abstract
Three studies have reported the results of phase 1 clinical trials of virotherapy for malignant gliomas, underscoring the momentum in the field. In the first study,1 investigators used a replication-competent, tumour-selective adenovirus to treat patients with recurrent glioblastomas. In a group in which patients received virus treatment only (n=25), 20% of the patients survived more than 3 years after treatment, and three patients had tumour volume reductions of 95% or more. In the second study,2 intratumoural infusion of a tumour-selective poliovirus into patients with recurrent malignant glioma improved overall survival, which reached a plateau of 21% at 24 months that was sustained at 36 months.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
